| Gina N Zilioli, MD | |
|
3555 Olentangy River Rd, Suite 3020, Columbus, OH 43214-3912 | |
| (614) 268-9487 | |
| (614) 262-7659 |
| Full Name | Gina N Zilioli |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 20 Years |
| Location | 3555 Olentangy River Rd, Columbus, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427183029 | NPI | - | NPPES |
| 2956010 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 35.093442 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
Biotechnology Industry Organization (BIO) President and Chief Executive Officer Jim Greenwood today issued the following statement in response to a risk assessment published today by the U.S. Food and Drug Administration (FDA) regarding the safety of milk and meat products from cloned animals and their offspring:
Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.
Low-risk Medicare patients entering home health care who received medication therapy management by phone were three times less likely to be hospitalized within the next two months, while those at greater risk saw no benefit, according to a study led by Purdue University.
Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the HIV drug market will grow to more than $8 billion by 2013.
› Verified 6 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
Biotechnology Industry Organization (BIO) President and Chief Executive Officer Jim Greenwood today issued the following statement in response to a risk assessment published today by the U.S. Food and Drug Administration (FDA) regarding the safety of milk and meat products from cloned animals and their offspring:
Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.
Low-risk Medicare patients entering home health care who received medication therapy management by phone were three times less likely to be hospitalized within the next two months, while those at greater risk saw no benefit, according to a study led by Purdue University.
Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the HIV drug market will grow to more than $8 billion by 2013.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gina N Zilioli, MD 3555 Olentangy River Rd, Suite 3020, Columbus, OH 43214-3912 Ph: (614) 268-9487 | Gina N Zilioli, MD 3555 Olentangy River Rd, Suite 3020, Columbus, OH 43214-3912 Ph: (614) 268-9487 |
News Archive
Biotechnology Industry Organization (BIO) President and Chief Executive Officer Jim Greenwood today issued the following statement in response to a risk assessment published today by the U.S. Food and Drug Administration (FDA) regarding the safety of milk and meat products from cloned animals and their offspring:
Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.
Low-risk Medicare patients entering home health care who received medication therapy management by phone were three times less likely to be hospitalized within the next two months, while those at greater risk saw no benefit, according to a study led by Purdue University.
Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the HIV drug market will grow to more than $8 billion by 2013.
› Verified 6 days ago
Sethu M. Madhavan, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 300 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3387 Fax: 614-366-0073 | |
Amrik Singh Khalsa, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 700 Childrens Dr, Columbus, OH 43205 Phone: 614-722-2000 Fax: 614-722-4966 | |
Samuel Y. Han, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-6255 Fax: 614-293-1456 | |
Dr. Ruchi Bhatia, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3400 Olentangy River Rd, Columbus, OH 43202 Phone: 614-754-5500 Fax: 614-457-9519 | |
Adam T. Ramey, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-7499 Fax: 614-366-2360 | |
Albert J. Cook, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-2957 Fax: 614-685-6533 | |
Walter G. Hanel Iv, MD, PHD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3196 Fax: 614-293-4812 |